Nuvation Bio prices $250M convertible notes offering at 0.75%, convertible at $7.84/share

Filed June 29, 2026 · ~2 min read

Key Changes

• high

  Nuvation Bio is offering $250 million of 0.75% convertible senior notes due 2032, convertible at $7.84 per share (127.4941 shares per $1,000 note). Underwriters have a $37.5 million over-allotment option.

  The Offering verify on EDGAR →
• high

  Net proceeds of $241.2 million will fund a $14.9 million capped call transaction (to reduce dilution), repay a $50 million secured loan in full, and support general corporate purposes.

  Use of Proceeds verify on EDGAR →
• high

  The notes are unsecured and rank junior to secured debt and structurally junior to all subsidiary liabilities ($32.6 million as of March 31, 2026). Pro forma total debt after the offering and loan repayment would be $255.8 million.

  Risk Factors verify on EDGAR →